US20110059969A1 - Piperazines as anti-obesity agents - Google Patents

Piperazines as anti-obesity agents Download PDF

Info

Publication number
US20110059969A1
US20110059969A1 US12/744,359 US74435908A US2011059969A1 US 20110059969 A1 US20110059969 A1 US 20110059969A1 US 74435908 A US74435908 A US 74435908A US 2011059969 A1 US2011059969 A1 US 2011059969A1
Authority
US
United States
Prior art keywords
carboxylate
piperazine
methyl
morpholin
ylmethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/744,359
Other languages
English (en)
Inventor
Joseph W. Boyd
Giles A. Brown
Michael Higginbottom
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Priority to US12/744,359 priority Critical patent/US20110059969A1/en
Assigned to BIOVITRUM AB reassignment BIOVITRUM AB ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BROWN, GILES A., HIGGINBOTTOM, MICHAEL, BOYD, JOSEPH W.
Assigned to ASTRAZENECA AB reassignment ASTRAZENECA AB ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BIOVITRUM AB
Publication of US20110059969A1 publication Critical patent/US20110059969A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings

Definitions

  • the present invention relates to new piperazine derivatives, to pharmaceutical compositions comprising these compounds, to processes for their preparation, and to the use of these compounds as leptin receptor modulator mimetics in the preparation of medicaments against conditions associated with weight gain, type 2 diabetes and dyslipidemias.
  • the first line of treatment is to offer diet and life style advice to patients, such as reducing the fat content of their diet and increasing their physical activity.
  • patients may also need to undergo drug therapy to maintain the beneficial results obtained from adapting the aforementioned diet and lifestyle changes.
  • Leptin is a hormone synthesized in fat cells that is believed to act in the hypothalamus to reduce food intake and body weight (see, e.g., Bryson, J. M. (2000) Diabetes, Obesity and Metabolism 2: 83-89).
  • Leptin has recently been associated with inflammation. It has been reported that circulating leptin levels rise during bacterial infection and in inflammation (see Otero, M et al. (2005) FEBS Lett. 579: 295-301 and references therein). Leptin can also act to increase inflammation by enhancing the release of pro-inflammatory cytokines TNF and IL-6 from inflammatory cells (Zarkesh-Esfahani, H. et al. (2001) J. Immunol. 167: 4593-4599). These agents in turn can contribute to the insulin resistance commonly seen in obese patients by reducing the efficacy of insulin receptor signaling (Lyon, C. J. et al. (2003) Endocrinol. 44: 2195-2200).
  • Continuous low grade inflammation is believed to be associated with obesity (in the presence and absence of insulin resistance and Type II diabetes) (Browning et al. (2004) Metabolism 53: 899-903, Inflammatory markers elevated in blood of obese women; Mangge et al. (2004) Exp. Clin. Endocrinol. Diabetes 112: 378-382, Juvenile obesity correlates with serum inflammatory marker C-reactive protein; Maachi et al. (2004) Int. J. Obes. Relat. Metab. Disord. 28: 993-997, Systemic low grade inflammation in obese people).
  • Leptin has also been implicated in the process of atherogenesis, by promoting lipid uptake into macrophages and endothelial dysfunction, thus promoting the formation of atherosclerotic plaques (see Lyon, C. J. et al. (2003) Endocrinol. 144: 2195-2200).
  • Leptin has also been shown to promote the formation of new blood vessels (angiogenesis) a process implicated in the growth of adipose tissue (Bouloumie A, et al. (1998) Circ. Res. 83: 1059-1066). Angiogenesis has also been implicated in diabetic retinopathy (Suganami, E. et al. (2004) Diabetes. 53: 2443-2448).
  • Angiogenesis is also believed to be involved with the growth of new blood vessels that feed abnormal tumour cells. Elevated leptin levels have been associated with a number of cancers, in particular breast, prostate and gastrointestinal cancers in humans (Somasundar P. et al. (2004) J. Surg. Res. 116: 337-349).
  • Leptin receptor agonists may also be used in the manufacture of a medicament to promote wound healing (Gorden, P. and Grajova, O. (2003) Current Opinion in Pharmacology 3: 655-659).
  • elevating leptin signaling in the brain may represent an approach for the treatment of depressive disorders (Lu, Xin-Yun et al. (2006) PNAS 103: 1593-1598).
  • compounds with leptin receptor agonistic like properties can be useful for the treatment of disorders relating to leptin signaling, as well as conditions associated with weight gain, such as obesity.
  • compounds with leptin receptor antagonistic like properties could be useful for the treatment of inflammation, atherosclerosis, diabetic retinopathy and nephropathy.
  • the invention relates to a compound of formula (I),
  • X is selected from O, S, N(R 1 ) and CH(R 2 ), provided that the ring containing X is not 3-pyrrolidine;
  • Y is CH 2 , O or N(R 5 );
  • R 1 is independently selected from hydrogen, C 1-6 -alkyl (unsubstituted or optionally substituted with one or more substituents independently selected from halogen, hydroxy, cyano and C 1-6 -alkoxy) and C 1-6 -acyl (unsubstituted or optionally substituted with one or more substituents independently selected from halogen, hydroxy and C 1-6 -alkoxy);
  • R 2 and R 3 are independently selected from hydrogen, halogen, hydroxy, C 1-6 -alkyl (unsubstituted or optionally substituted with one or more substituents independently selected from halogen, hydroxy and C 1-6 -alkoxy) and C 1-6 -alkoxy (unsubstituted or optionally substituted with one or more substituents independently selected from halogen, hydroxy and C 1-6 -alkoxy);
  • R 4 is independently selected from hydrogen, halogen, hydroxy, cyano, nitro, CF 3 , C 1-6 -alkyl and C 1-6 -alkoxy;
  • R 5 is hydrogen or C 1-4 -alkyl
  • a, b and c are each independently 1, 2 or 3;
  • d 0, 1 or 2;
  • e 1, 2 or 3;
  • f and g are each independently 0, 1 or 2.
  • Y is O.
  • X is preferably selected from O, N(R 1 ) and CH(R 2 ).
  • R 1 is preferably selected from hydrogen, C 1-4 -alkyl and C 1-4 -acyl.
  • R 1 is hydrogen, methyl or acetyl.
  • R 2 and R 3 are preferably independently selected from hydrogen and C 1-4 -alkyl.
  • R 2 and R 3 are hydrogen.
  • R 4 is preferably independently selected from hydrogen, halogen, CF 3 and C 1-4 -alkyl.
  • R 4 is independently selected from hydrogen, fluoro, chloro or methyl.
  • d and f are each preferably 1.
  • e is preferably 1 or 2.
  • g is preferably 0 or 1, and more preferably 0.
  • Particular preferred compounds of formula (I) are the compounds of formula (I′)
  • X 1 and X 2 are each independently selected from O, N(R 1 ) or CH(R 2 ), provided that at least one of X 1 and X 2 is N(R 1 );
  • R 1 is as defined in formula (I), and preferably hydrogen, methyl or acetyl
  • R 2 is as defined in formula (I), and preferably hydrogen
  • R 4 is hydrogen, fluoro, chloro or methyl
  • c is 1, 2 or 3;
  • e 1 or 2;
  • g 0 or 1.
  • Another aspect of the present invention is a compound of formula (I) for use in therapy.
  • the invention relates to a compound of formula (I) for use in the treatment or prevention of any of the disorders or conditions described herein.
  • the invention relates to the use of a compound of formula (I) in the manufacture of a medicament for the treatment or prevention of any of the disorders or conditions described herein.
  • said compounds may be used in the manufacture of a medicament for the treatment or prevention of a condition that is prevented, treated, or ameliorated by selective action on the leptin receptor.
  • said compounds may be used in the manufacture of a medicament for the treatment or prevention of conditions (in particular, metabolic conditions) that are associated with weight gain.
  • Conditions associated with weight gain include diseases, disorders, or other conditions that have an increased incidence in obese or overweight subjects. Examples include: lipodystrophy, HIV lipodystrophy, diabetes (type 2), insulin resistance, metabolic syndrome, hyperglycemia, hyperinsulinemia, dyslipidemia, hepatic steatosis, hyperphagia, hypertension, hypertriglyceridemia, infertility, a skin disorder associated with weight gain, macular degeneration.
  • the compounds may also be used in the manufacture of a medicament for maintaining weight loss of a subject.
  • compounds of formula (I) which are leptin receptor agonist mimetics may also be used in the manufacture of a medicament to promote wound healing.
  • compounds of formula (I) which are leptin receptor agonist mimetics may also be used in the manufacture of a medicament for the treatment or prevention of conditions that cause a decrease in circulating leptin concentrations, and the consequent malfunction of the immune and reproductive systems.
  • conditions and malfunctions include severe weight loss, dysmenorrhea, amenorrhea, female infertility, immunodeficiency and conditions associated with low testosterone levels.
  • compounds of formula (I) which are leptin receptor agonist mimetics may also be used in the manufacture of a medicament for the treatment or prevention of conditions caused as a result of leptin deficiency, or a leptin or leptin receptor mutation.
  • compounds of formula (I) which are leptin receptor antagonist mimetics may be used for the treatment or prevention of inflammatory conditions or diseases, low level inflammation associated with obesity and excess plasma leptin and in reducing other complications associated with obesity including atherosclerosis, and for the correction of insulin resistance seen in Metabolic Syndrome and diabetes.
  • compounds of formula (I) which are leptin receptor antagonist mimetics can be used for the treatment or prevention of inflammation caused by or associated with: cancer (such as leukemias, lymphomas, carcinomas, colon cancer, breast cancer, lung cancer, pancreatic cancer, hepatocellular carcinoma, kidney cancer, melanoma, hepatic, lung, breast, and prostate metastases, etc.); auto-immune disease (such as organ transplant rejection, lupus erythematosus, graft v.
  • cancer such as leukemias, lymphomas, carcinomas, colon cancer, breast cancer, lung cancer, pancreatic cancer, hepatocellular carcinoma, kidney cancer, melanoma, hepatic, lung, breast, and prostate metastases, etc.
  • auto-immune disease such as organ transplant rejection, lupus erythematosus, graft v.
  • autoimmune damage including multiple sclerosis, Guillam Barre Syndrome, myasthenia gravis
  • cardiovascular conditions associated with poor tissue perfusion and inflammation such as atheromas, atherosclerosis, stroke, ischaemia-reperfusion injury, claudication, spinal cord injury, congestive heart failure, vasculitis, haemorrhagic shock, vasospasm following subarachnoid haemorrhage, vasospasm following cerebrovascular accident, pleuritis, pericarditis, the cardiovascular complications of diabetes); ischaemia-reperfusion injury, ischaemia and associated inflammation, restenosis following angioplasty and inflammatory aneurysms; epilepsy, neurodegeneration (including Alzheimer's Disease), arthritis (such as rheumatoid arthritis, osteoarthritis
  • chronic obstructive pulmonary disease impeded and obstructed airways, bronchoconstriction, pulmonary vasoconstriction, impeded respiration, chronic pulmonary inflammatory disease, silicosis, pulmonary sarcosis, cystic fibrosis, pulmonary hypertension, pulmonary vasoconstriction, emphysema, bronchial allergy and/or inflammation, asthma, hay fever, rhinitis, vernal conjunctivitis and adult respiratory distress syndrome); conditions associated with inflammation of the skin (including psoriasis, eczema, ulcers, contact dermatitis); conditions associated with inflammation of the bowel (including Crohn's disease, ulcerative colitis and pyresis, irritable bowel syndrome, inflammatory bowel disease); HIV (particularly HIV infection), cerebral malaria, bacterial meningitis, osteoporosis and other bone resorption diseases, osteoarthritis, infertility from endometriosis, fever and myal
  • compounds of formula (I) which are leptin receptor antagonists mimetics may be used for the treatment or prevention of macro or micro vascular complications of type 1 or 2 diabetes, retinopathy, nephropathy, autonomic neuropathy, or blood vessel damage caused by ischaemia or atherosclerosis.
  • compounds of formula (I) which are leptin receptor antagonist mimetics may be used to inhibit angiogenesis.
  • Compounds of the invention that inhibit angiogenesis may be used for the treatment or prevention of obesity or complications associated with obesity.
  • Compounds of the invention that inhibit angiogenesis may be used for the treatment or prevention of complications associated with inflammation diabetic retinopathy, or tumour growth particularly in breast, prostate or gastrointestinal cancer.
  • the invention relates to a method for the treatment or prevention of any of the disorders or conditions described herein, which includes administering to a subject (e.g., a subject in need thereof, e.g., a mammal) an effective amount of a compound of formula I.
  • a subject e.g., a subject in need thereof, e.g., a mammal
  • Methods delineated herein include those wherein the subject is identified as in need of a particular stated treatment. Identifying a subject in need of such treatment can be in the judgment of a subject or a health care professional and can be subjective (e.g. opinion) or objective (e.g. measurable by a test or diagnostic method).
  • the methods herein include those further comprising monitoring subject response to the treatment administrations.
  • monitoring may include periodic sampling of subject tissue, fluids, specimens, cells, proteins, chemical markers, genetic materials, etc. as markers or indicators of the treatment regimen.
  • the subject is prescreened or identified as in need of such treatment by assessment for a relevant marker or indicator of suitability for such treatment.
  • the invention provides a method of monitoring treatment progress.
  • the method includes the step of determining a level of diagnostic marker (Marker) (e.g., any target or cell type delineated herein modulated by a compound herein) or diagnostic measurement (e.g., screen, assay) in a subject suffering from or susceptible to a disorder or symptoms thereof delineated herein, in which the subject has been administered a therapeutic amount of a compound herein sufficient to treat the disease or symptoms thereof.
  • the level of Marker determined in the method can be compared to known levels of Marker in either healthy normal controls or in other afflicted patients to establish the subject's disease status.
  • a second level of Marker in the subject is determined at a time point later than the determination of the first level, and the two levels are compared to monitor the course of disease or the efficacy of the therapy.
  • a pre-treatment level of Marker in the subject is determined prior to beginning treatment according to this invention; this pre-treatment level of Marker can then be compared to the level of Marker in the subject after the treatment commences, to determine the efficacy of the treatment.
  • a level of Marker or Marker activity in a subject is determined at least once. Comparison of Marker levels, e.g., to another measurement of Marker level obtained previously or subsequently from the same patient, another patient, or a normal subject, may be useful in determining whether therapy according to the invention is having the desired effect, and thereby permitting adjustment of dosage levels as appropriate. Determination of Marker levels may be performed using any suitable sampling/expression assay method known in the art or described herein. Preferably, a tissue or fluid sample is first removed from a subject. Examples of suitable samples include blood, urine, tissue, mouth or cheek cells, and hair samples containing roots. Other suitable samples would be known to the person skilled in the art.
  • Determination of protein levels and/or mRNA levels (e.g., Marker levels) in the sample can be performed using any suitable technique known in the art, including, but not limited to, enzyme immunoassay, ELISA, radio labeling/assay techniques, blotting/chemiluminescence methods, real-time PCR, and the like.
  • a compound of formula (I) it may be advantageous if a compound of formula (I) is able to penetrate the central nervous system. In other embodiments, it may be advantageous if a compound of formula (I) is not able to penetrate the CNS.
  • compounds that are leptin receptor agonist mimetics may be particularly useful for the treatment or prevention of obesity, insulin resistance, or diabetes (particularly glucose intolerance) if these compounds can penetrate the CNS.
  • a person of ordinary skill in the art can readily determine whether a compound can penetrate the CNS. A suitable method that may be used is described in the Biological Methods section.
  • a leptin receptor response may be measured in any suitable way. In vitro, this may be done be measuring leptin receptor signaling. For example, phosphorylation of Akt, STAT3, STAT5, MAPK, shp2 or the leptin receptor in response to binding of leptin or a compound of the invention to the leptin receptor may be measured. The extent of phosphorylation of Akt, STAT3, STAT5, MAPK, shp2 or the leptin receptor may be determined for example by Western blotting or by ELISA. Alternatively, a STAT reporter assay may be used, for example STAT driven luciferase expression. A cell line expressing the leptin receptor may be used for such assays. In vivo, leptin receptor response may be measured by determining the reduction in food intake and body weight after administration of leptin or a compound of the invention.
  • Biological Methods below describe assays and methods that can be used to determine whether a compound of the invention is a leptin receptor agonist mimetic or a leptin receptor antagonist mimetic.
  • a compound of formula (I) may be administered with or without other therapeutic agents.
  • the compound may be administered with an anti-inflammatory agent (for example, disease modifying anti-rheumatic drugs such as methotrexate, sulphasalazine and cytokine inactivating agents, steroids, NSAIDs, cannabinoids, tachykinin modulators, or bradykinin modulators).
  • an anti-inflammatory agent for example, disease modifying anti-rheumatic drugs such as methotrexate, sulphasalazine and cytokine inactivating agents, steroids, NSAIDs, cannabinoids, tachykinin modulators, or bradykinin modulators.
  • a compound of formula (I) may be administered with a cytotoxic agent (for example, methotrexate, cyclophosphamide) or another anti-tumour drug.
  • Compounds of formula (I) may be radio labeled (for example with tritium or radioactive iodine) for in vitro or in vivo applications, such as receptor displacement studies or receptor imaging.
  • a further aspect of the present invention relates to processes for the manufacture of compounds of formula (I) as defined above.
  • the process comprises:
  • R 3 , R 4 , b, c, f and g are as defined in formula (I), with 4-nitrophenyl chloroformate or bis-(4-nitrophenyl)carbonate in the presence of a suitable base (such as DIPEA or NEt 3 ) in a suitable solvent (such as DCM or THF), at ⁇ 10 to 40° C., to form a compound of formula (III):
  • a suitable base such as DIPEA or NEt 3
  • a suitable solvent such as DCM or THF
  • X, R 1 , R 2 , a, d and e are as defined in formula (I), in the presence of a suitable base, (such as NaH or NMM), in a suitable solvent (such as THF or DCM), at ⁇ 10 to 40° C., to obtain a compound of formula (I); and
  • a suitable base such as NaH or NMM
  • a suitable solvent such as THF or DCM
  • the process comprises:
  • R 3 , R 4 , b, c, f and g are as defined in formula (I), in the presence of a suitable base, (such as DIPEA), in a suitable solvent (such as DCM or DMF), at ⁇ 10 to 40° C., to obtain a compound of formula (I); and
  • a suitable base such as DIPEA
  • a suitable solvent such as DCM or DMF
  • C 1-6 -alkyl denotes a straight or branched alkyl group having from 1 to 6 carbon atoms.
  • Examples of said C 1-6 -alkyl include methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, t-butyl, and straight- and branched-chain pentyl and hexyl.
  • C 1-6 -alkyl For parts of the range “C 1-6 -alkyl” all subgroups thereof are contemplated such as C 1-5 -alkyl, C 1-4 -alkyl, C 1-3 -alkyl, C 1-2 -alkyl, C 2-6 -alkyl, C 2-5 -alkyl, C 2-4 -alkyl, C 2-3 -alkyl, C 3-6 -alkyl, C 4-5 -alkyl, etc.
  • C 1-6 -acyl denotes a carbonyl group that is attached through its carbon atom to a hydrogen atom (i.e., a formyl group) or to a straight or branched C 1-5 -alkyl group, where alkyl is defined as above.
  • Examples of said C 1-6 -acyl include formyl, acetyl, propionyl, n-butyryl, 2-methylpropionyl and n-pentoyl.
  • C 1-6 -acyl For parts of the range “C 1-6 -acyl” all subgroups thereof are contemplated such as C 1-5 -acyl, C 1-4 -acyl, C 1-3 -acyl, C 1-2 -acyl, C 2-6 -acyl, C 2-5 -acyl, C 2-4 -acyl, C 2-3 -acyl, C 3-6 -acyl, C 4-5 -acyl, etc. If a C 1-6 -acyl group is optionally substituted with one or more substituents independently selected from halogen, hydroxy and C 1-6 -alkoxy, said substituent can not be attached to the carbonyl carbon atom.
  • C 1-6 -alkoxy denotes a straight or branched alkoxy group having from 1 to 6 carbon atoms.
  • Examples of said C 1-6 -alkoxy include methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, iso-butoxy, sec-butoxy, t-butoxy, and straight- and branched-chain pentoxy and hexoxy.
  • C 1-6 -alkoxy For parts of the range “C 1-6 -alkoxy” all subgroups thereof are contemplated such as C 1-5 -alkoxy, C 1-4 -alkoxy, C 1-3 -alkoxy, C 1-2 -alkoxy, C 2-6 -alkoxy, C 2-5 -alkoxy, C 2-4 -alkoxy, C 2-3 -alkoxy, C 3-6 -alkoxy, C 4-5 -alkoxy, etc.
  • Halogen refers to fluorine, chlorine, bromine or iodine.
  • Haldroxy refers to the —OH radical.
  • Niro refers to the —NO 2 radical.
  • mammal includes organisms, which include mice, rats, cows, sheep, pigs, rabbits, goats, and horses, monkeys, dogs, cats, and preferably humans.
  • the subject may be a human subject or a non human animal, particularly a domesticated animal, such as a dog.
  • “Pharmaceutically acceptable” means being useful in preparing a pharmaceutical composition that is generally safe, non-toxic and neither biologically nor otherwise undesirable and includes being useful for veterinary use as well as human pharmaceutical use.
  • Treatment includes prophylaxis of the named disorder or condition, or amelioration or elimination of the disorder once it has been established.
  • “An effective amount” refers to an amount of a compound that confers a therapeutic effect (e.g., treats, controls, ameliorates, prevents, delays the onset of, or reduces the risk of developing a disease, disorder, or condition or symptoms thereof) on the treated subject.
  • the therapeutic effect may be objective (i.e., measurable by some test or marker) or subjective (i.e., subject gives an indication of or feels an effect).
  • Prodrugs refers to compounds that may be converted under physiological conditions or by solvolysis to a biologically active compound of formula (I).
  • a prodrug may be inactive when administered to a subject in need thereof, but is converted in vivo to an active compound of formula (I).
  • Prodrugs are typically rapidly transformed in vivo to yield the parent compound, e.g. by hydrolysis in the blood.
  • the prodrug compound usually offers advantages of solubility, tissue compatibility or delayed release in a mammalian organism (see Silverman, R. B., The Organic Chemistry of Drug Design and Drug Action, 2 nd Ed., Elsevier Academic Press (2004), pp. 498-549).
  • Prodrugs may be prepared by modifying functional groups, such as a hydroxy, amino or mercapto groups, present in a compound of formula (I) in such a way that the modifications are cleaved, either in routine manipulation or in vivo, to the parent compound.
  • Examples of prodrugs include, but are not limited to, acetate, formate and succinate derivatives of hydroxy functional groups or phenyl carbamate derivatives of amino functional groups.
  • a given chemical formula or name shall also encompass all salts, hydrates, solvates, N-oxides and prodrug forms thereof. Further, a given chemical formula or name shall encompass all tautomeric and stereoisomeric forms thereof.
  • Stereoisomers include enantiomers and diastereomers. Enantiomers can be present in their pure forms, or as racemic (equal) or unequal mixtures of two enantiomers. Diastereomers can be present in their pure forms, or as mixtures of diastereomers. Diastereomers also include geometrical isomers, which can be present in their pure cis or trans forms or as mixtures of those.
  • the compounds of formula (I) may be used as such or, where appropriate, as pharmacologically acceptable salts (acid or base addition salts) thereof
  • pharmacologically acceptable addition salts are meant to comprise the therapeutically active non-toxic acid and base addition salt forms that the compounds are able to form.
  • Compounds that have basic properties can be converted to their pharmaceutically acceptable acid addition salts by treating the base form with an appropriate acid.
  • Exemplary acids include inorganic acids, such as hydrogen chloride, hydrogen bromide, hydrogen iodide, sulphuric acid, phosphoric acid; and organic acids such as formic acid, acetic acid, propanoic acid, hydroxyacetic acid, lactic acid, pyruvic acid, glycolic acid, maleic acid, malonic acid, oxalic acid, benzenesulphonic acid, toluenesulphonic acid, methanesulphonic acid, trifluoroacetic acid, fumaric acid, succinic acid, malic acid, tartaric acid, citric acid, salicylic acid, p-aminosalicylic acid, pamoic acid, benzoic acid, ascorbic acid and the like.
  • organic acids such as formic acid, acetic acid, propanoic acid, hydroxyacetic acid, lactic acid, pyruvic acid, glycolic acid, maleic acid, malonic acid, oxalic acid, benzenesulphonic acid, toluen
  • Exemplary base addition salt forms are the sodium, potassium, calcium salts, and salts with pharmaceutically acceptable amines such as, for example, ammonia, alkylamines, benzathine, and amino acids, such as, e.g. arginine and lysine.
  • the term addition salt as used herein also comprises solvates which the compounds and salts thereof are able to form, such as, for example, hydrates, alcoholates and the like.
  • the compounds of the invention are formulated into pharmaceutical formulations for various modes of administration. It will be appreciated that compounds of the invention may be administered together with a physiologically acceptable carrier, excipient, or diluent.
  • the pharmaceutical compositions of the invention may be administered by any suitable route, preferably by oral, rectal, nasal, topical (including buccal and sublingual), sublingual, transdermal, intrathecal, transmucosal or parenteral (including subcutaneous, intramuscular, intravenous and intradermal) administration.
  • Other formulations may conveniently be presented in unit dosage form, e.g., tablets and sustained release capsules, and in liposomes, and may be prepared by any methods well known in the art of pharmacy.
  • compositions are usually prepared by mixing the active substance, or a pharmaceutically acceptable salt thereof, with conventional pharmaceutically acceptable carriers, diluents or excipients.
  • excipients are water, gelatin, gum arabicum, lactose, microcrystalline cellulose, starch, sodium starch glyco late, calcium hydrogen phosphate, magnesium stearate, talcum, colloidal silicon dioxide, and the like.
  • Such formulations may also contain other pharmacologically active agents, and conventional additives, such as stabilizers, wetting agents, emulsifiers, flavouring agents, buffers, and the like.
  • the amount of active compounds is between 0.1-95% by weight of the preparation, preferably between 0.2-20% by weight in preparations for parenteral use and more preferably between 1-50% by weight in preparations for oral administration.
  • the formulations can be further prepared by known methods such as granulation, compression, microencapsulation, spray coating, etc.
  • the formulations may be prepared by conventional methods in the dosage form of tablets, capsules, granules, powders, syrups, suspensions, suppositories or injections.
  • Liquid formulations may be prepared by dissolving or suspending the active substance in water or other suitable vehicles. Tablets and granules may be coated in a conventional manner. To maintain therapeutically effective plasma concentrations for extended periods of time, compounds of the invention may be incorporated into slow release formulations.
  • the dose level and frequency of dosage of the specific compound will vary depending on a variety of factors including the potency of the specific compound employed, the metabolic stability and length of action of that compound, the patient's age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the condition to be treated, and the patient undergoing therapy.
  • the daily dosage may, for example, range from about 0.001 mg to about 100 mg per kilo of body weight, administered singly or multiply in doses, e.g. from about 0.01 mg to about 25 mg each. Normally, such a dosage is given orally but parenteral administration may also be chosen.
  • the compounds of formula (I) above may be prepared by, or in analogy with, conventional methods. Formation of the central urethane or urea linker is the key synthetic step in preparing the compounds formula (I).
  • a large number of activating reagents can be used for the formation of a urethane or urea linker e.g. phosgene to form chloroformate of alcohols, or carbonyldiimidazole (CDI) to form imidazole carboxylates.
  • the urethane linkers incorporated into compounds of formula (I) have been synthesized utilizing 4-nitrophenyl chloroformate or bis-(4-nitrophenyl)carbonate as the activating agent.
  • the preparation of intermediates and compounds according to the examples of the present invention may in particular be illuminated by the following Schemes 1 and 2. Definitions of variables in the structures in the schemes herein are commensurate with those of corresponding positions in the formulae delineated herein.
  • the piperazine moiety is activated by treating piperazine derivative (II) with 4-nitrophenyl chloroformate or bis-(4-nitrophenyl)carbonate in the presence of a base (such as DIPEA) to form the corresponding carbamate derivative (III).
  • a base such as DIPEA
  • the alcohol moiety is activated by treating alcohol (IV) with 4-nitrophenyl chloroformate or bis-(4-nitrophenyl)carbonate in the presence of a base (such as DIPEA) to form the corresponding 4-nitrophenyl carbonate derivative (V).
  • a base such as DIPEA
  • the activated carbonate (V) is treated with the appropriate piperazine moiety (II) in the presence of a base (such as DIPEA), resulting in the formation of the desired compound of formula (I). This is generally represented in Scheme 2.
  • the formation of the urethane is typically a two step process but this may also be performed in a one-pot reaction by formation of the activated intermediate in situ.
  • the experimental section below gives examples of all of these synthetic alternatives.
  • a pharmaceutically acceptable acid addition salt may be obtained by dissolving the free base in a suitable organic solvent and treating the solution with an acid, in accordance with conventional procedures for preparing acid addition salts from base compounds. Examples of addition salt forming acids are mentioned above.
  • the compounds of formula (I) may possess one or more chiral carbon atoms, and they may therefore be obtained in the form of optical isomers, e.g., as a pure enantiomer, or as a mixture of enantiomers (racemate) or as a mixture containing diastereomers.
  • optical isomers e.g., as a pure enantiomer, or as a mixture of enantiomers (racemate) or as a mixture containing diastereomers.
  • the separation of mixtures of optical isomers to obtain pure enantiomers is well known in the art and may, for example, be achieved by fractional crystallization of salts with optically active (chiral) acids or by chromatographic separation on chiral columns.
  • the chemicals used in the synthetic routes delineated herein may include, for example, solvents, reagents, catalysts, and protecting group and deprotecting group reagents.
  • protecting groups are t-butoxycarbonyl (Boc), benzyl and trityl (triphenylmethyl).
  • the methods described above may also additionally include steps, either before or after the steps described specifically herein, to add or remove suitable protecting groups in order to ultimately allow synthesis of the compounds.
  • various synthetic steps may be performed in an alternate sequence or order to give the desired compounds. Synthetic chemistry transformations and protecting group methodologies (protection and deprotection) useful in synthesizing applicable compounds are known in the art and include, for example, those described in R.
  • FIG. 1 shows an example of body weight separation between animals fed on a high carbohydrate diet.
  • the error bars represent mean +/ ⁇ SEM.
  • FIG. 2 shows the cumulative body weight change (%) observed in a 4 day study in DIO rats for Example 7.
  • FIG. 3 shows the cumulative body weight change (%) observed in a 4 day study in DIO rats for Example 20.
  • FIG. 4 shows the cumulative body weight change (%) observed in a 4 day study in DIO rats for Example 30.
  • FIG. 5 shows the concentration-dependent increase in [ 3 H]-thymidine incorporation by JEG-3 cells for leptin.
  • Spectra are acquired in positive electrospray mode. The acquired mass range was m/z 100-1100. Profile detection of the mass peaks was used. Flash chromatography was performed on a Flash Master Personal system equipped with Strata SI-1 silica gigatubes. Reverse phase chromatography was performed on a Gilson system equipped with Merck LiChoprep® RP-18 (40-63 ⁇ m) 460 ⁇ 26 mm column, 30 mL/min, gradient of methanol in water. Preparative HPLC was performed on a Gilson system equipped with Phenomenex Hydro RP 15 0 ⁇ 20 mm, 20 mL/min, gradient of acetonitrile in water. The compounds were automatically named using ACD 6.0 or 8.0.
  • Morpholine-3,4-dicarboxylic acid 4-tert-butyl ester (9.50 g, 41 mmol) was dissolved in anhydrous THF (50 mL) under nitrogen and cooled to ⁇ 10° C. A 1M solution of borane (82 mL, 82 mmol) was added dropwise whilst maintaining the temperature below 0° C. The reaction mixture was allowed to warm to room temperature and stirred overnight. The reaction mixture was cooled to ⁇ 5° C. and water (10 mL) was added cautiously followed by Na 2 CO 3 (9.5 g) in water (20 mL). After stirring for 30 min at room temperature the THF was removed in vacuo, water was added and the reaction mixture was extracted with diethylether ( ⁇ 3).
  • the yellow solid was recrystallised from a mixture of hexane and toluene (3:7) using charcoal to give 4-(2,4-difluorophenyl)-piperazine-1-carboxylic acid 4-nitrophenyl ester (4.3 g, 63%) as a yellow crystalline solid.
  • reaction mixture was allowed to warm to room temperature and stirred for 18 hours. The reaction mixture was then cooled to 0° C. and quenched with the drop-wise addition of sat aq NaHCO 3 solution and concentrated in vacuo. The residue was dissolved in ethyl acetate (200 mL), washed with sat aq NaHCO 3 solution (4 ⁇ 50 mL), dried (MgSO 4 ) and concentrated in vacuo. The residue was purified by reverse phase chromatography (gradient eluting with methanol in water, with 1% formic acid in each solvent, 0-25%).
  • reaction mixture was allowed to warm to room temperature, stirred for 16 hours, the reaction mixture was cooled to 0° C. then quenched with the drop-wise addition of sat aq NaHCO 3 solution and concentrated in vacuo.
  • the residue was dissolved in EtOAc (200 mL), washed with sat aq NaHCO 3 solution (4 ⁇ 50 mL), dried (MgSO 4 ) and concentrated in vacuo.
  • the residue was suspended in water:formic acid solution [1:1] (20 mL), filtered and the filtrate was purified by reverse phase column chromatography (gradient eluting with methanol in water, with 1% formic acid in each solvent, 0-15%).
  • the residue was purified by reverse phase column chromatography (LiChroprep RP-18, 40-63 ⁇ m, 460 ⁇ 26 mm (100 g), 30 mL/min, gradient 0% to 30% (over 75 min) to 100% (over 13 min) MeOH in water with 1% formic acid).
  • the residue was de-salted using K 2 CO 3 in DCM to give [(2S)-1,4-dimethylpiperazin-2-yl]methyl 4-(4-fluorophenyl)piperazine-1-carboxylate (1.78 g, 60.0%) as a light yellow gum.
  • the THF was removed in vacuo and transferred to a separating funnel where the organic product was extracted with EtOAc (3 ⁇ 75 mL). The combined organic extracts were collected together and washed with saturated aqueous NaHCO 3 solution (3 ⁇ 75 mL). The organic layer was dried (MgSO 4 ), filtered and concentrated in vacuo to give a crude yellow slurry.
  • the crude residue was purified by reverse phase column chromatography (LiChroprep RP-18, 40-63 ⁇ m, 460 ⁇ 26 mm (100 g), 30 mL/min, gradient 0% to 15% (over 70 min) to 100% (over 5 min) MeOH in water with 1% formic acid).
  • the residue was purified by reverse phase column chromatography (LiChroprep RP-18, 40-63 ⁇ m, 460 ⁇ 26 mm (100 g), 30 mL/min, gradient 0% to 30% (over 75 min) to 100% (over 13 min) MeOH in water with 1% formic acid).
  • the residue was de-salted using K 2 CO 3 in DCM to give [(2S)-1,4-dimethylpiperazin-2-yl]methyl 4-(2,4-difluorophenyl)piperazine-1-carboxylate (1.23 g, 39.4%) as a light yellow gum.
  • 1,4-dimethyl-2-hydroxymethyl piperazine (1.00 g, 6.94 mmol) was dissolved in DCM (50 mL) at room temperature and NMM (0.74 g, 7.29 mmol) was added. The reaction mixture was cooled to 0° C. and 4-nitrophenylchloroformate (1.4 g, 6.94 mmol) was added. The reaction mixture was stirred at room temperature for 4 h and then divided into two equal volumes. To one portion was added DIPEA (1.35 g, 10.4 mmol), 1-benzyl piperazine (0.61 g, 3.47 mmol) and the reaction mixture was stirred for 4 h.
  • the residue was purified by reverse phase column chromatography (LiChroprep RP-18, 40-63 ⁇ m, 460 ⁇ 26 mm (100 g), 30 mL/min, gradient 0% to 30% (over 88 min) MeOH in water with 1% formic acid).
  • the residue was de-salted using K 2 CO 3 in DCM to give (1,4-dimethylpiperazin-2-yl)methyl 4-benzylpiperazine-1-carboxylate (0.32 g, 26.3%) as a light yellow oil.
  • Morpholin-2-ylmethyl 4-phenylpiperazine-1-carboxylate (non-HC1 salt of Example 10; 1.00 g, 3.27 mmol) and 37% formaldehyde in water (1.97 g, 1.82 mL, 65.5 mmol) were dissolved in MeOH (20 mL) at room temperature followed by addition of sodium triacetoxyborohydride (2.78 g, 13.1 mmol) portionwise over 5 minutes. The reaction mixture was stirred for 2 h. The reaction mixture was quenched by the addition of saturated aq Na 2 CO 3 solution. The solvents were removed in vacuo and the residual aqueous phase was loaded onto an Isolute HM-N 20 mL cartridge.
  • the solvent was removed in vacuo and the residue was repurified by reverse phase column chromatography (LiChroprep RP-18, 40-63 ⁇ m, 460 ⁇ 26 mm (100 g), 30 mL/min, gradient 0% to 20% (over 70 min) then held at 20% (over 120 min) MeOH in water with 1% formic acid.
  • the solvent was removed in vacuo and the residue was de-salted using K 2 CO 3 in DCM.
  • reaction mixture was diluted with THF (50 mL), stirred for lh at room temperature, filtered and the filtrate was concentrated in vacuo. The residue was dissolved in DCM, dried (MgSO 4 ) and the solvent removed in vacuo to give (4-methyl-morpholin-3-yl)-methanol (2.05 g, 85%) as a colourless liquid.
  • reaction mixture was quenched with the addition of aqueous NaHCO 3 (0.5 mL) at 0° C. and the solvents removed in vacuo.
  • the residue was suspended between aq Na 2 CO 3 (20 mL) and EtOAc (20 mL).
  • the aqueous phase was extracted with EtOAc (2 ⁇ 20 mL).
  • the combined organic layers were washed with aq Na 2 CO 3 (20 mL), dried (MgSO 4 ) and the solvent removed in vacuo.
  • reaction mixture was quenched with the addition of aqueous NaHCO 3 (0.5 mL) at 0° C.
  • the reaction mixture was stirred for 1 h and then the solvents were removed in vacuo.
  • the residue was suspended between water and EtOAc.
  • the aqueous phase was extracted with EtOAc ( ⁇ 3).
  • the combined organic layers were washed with aqueous Na 2 CO 3 , dried (MgSO 4 ) and the solvent removed in vacuo.
  • Rodent models of obesity are valuable tools for studying the underlying factors that contribute to the initiation and maintenance of the obese state in humans.
  • the model of diet-induced obesity (DIO) in rodents is particularly suited to this task as DIO rats share a number of traits with human obesity.
  • DIO diet-induced obesity
  • Rats predisposed to develop DIO will gain weight at rates comparable to rats fed a low-energy (chow) diet and will not become obese unless fed an HE diet.
  • the resulting weight gains and body composition changes persist, even when animals are switched back to a normal chow diet. Changes in body weight and composition, which occur during the development and perpetuation of the DIO and DR phenotypes, are associated with several alterations in brain function that may underlie these adjustments
  • Wistar male rats ( ⁇ 200-250 g at start of modified dietary intervention) are put on a high-carbohydrate (HE) diet for 8-10 weeks.
  • the composition of the diet is 33% (w/v) powdered chow (RM1), 33% (w/v) condensed milk (Nestle), 7% (w/v) Castor sugar (Tate & Lyle), and 27% (w/v) water.
  • Body weights are recorded and following an 8-week period, animals are separated in 2 groups according to their weight. As in any outbred strain of animals (rodents, primates) a population will naturally separate in two groups: individuals prone to obesity (putting on more weight) or obesity-resistant (putting on less weight).
  • FIG. 1 shows an example of body weight separation between animals fed on the highly palatable diet (high carbohydrate).
  • Obese-prone animals are treated with a compound of formula (I) and the effect on their body weight is measured.
  • the compounds are dosed bid at 10 mg/kg PO, with a dose-volume of 1 mL/kg or an equivalent vehicle dose (saline) for comparison.
  • the doses are administered AM (09:00) and PM (16:00) and the body weight is measured in the morning before dosing. There are typically 8 animals per group.
  • FIGS. 2 to 4 show the cumulative body weight change (%) observed in a 4 day study in DIO rats for Examples 7, 20 and 30, respectively.
  • leptin receptor expression in non-recombinant system is often fluctuating and care must be given to identify a system where signal stability remains within experiments.
  • leptin receptor antagonist mimetics could be identified by evaluating their action vs. leptin (see below).
  • Leptin is produced chiefly in adipose cells, but in humans, mRNA encoding leptin is also present in the placenta. Here, leptin might play an important proliferative role in the microvasculature. The possibility to use this hypothesis in a native cell line was evaluated.
  • JEG-3 cells choriocarcinoma cell line
  • leptin is able to stimulate proliferation up to 3 fold (Biol. Reprod. (2007) 76: 203-10).
  • the radioactivity incorporated by the cells is an index of their proliferative activity and is measured in counts per minute (CPM) with a liquid scintillation beta counter.
  • This finding can be applied to test whether a compound is able to either reproduce the effect of leptin on cell proliferation (leptin receptor agonist mimetic) (i.e., a given compound will cause an increase in incorporated [ 3 H]-Thymidine by the cells) or to inhibit the effect of leptin (antagonistic effect) by preventing the leptin-mediated increase in [ 3 H]-thymidine incorporation.
  • This approach has the advantage of using a non-recombinant system and has reasonable reproducibility and robustness.
  • test species is given a bolus dose of the substrate under investigation, usually via intravenous (IV) or oral (PO) routes.
  • IV intravenous
  • PO oral
  • blood samples are taken and the resultant plasma extracted and analysed for substrate concentration and, where appropriate, metabolite concentration.
  • animals from another group are sacrificed, brains isolated and the brain surface cleaned. Brain samples are then homogenised, extracted and analysed for substrate concentration and, where appropriate, metabolite concentration.
  • microdialysis probes are implanted into one or more brain regions of the test species and samples collected at appropriate time points for subsequent analysis. This method has the advantage of measuring only extra-cellular substrate concentration. Plasma and brain concentrations are then compared and ratios calculated, either by comparison of averaged concentrations at individual time points, or by calculation of the area-under-the-curve (AUC) of the concentration-time plots.
  • AUC area-under-the-curve

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
US12/744,359 2007-12-05 2008-12-05 Piperazines as anti-obesity agents Abandoned US20110059969A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/744,359 US20110059969A1 (en) 2007-12-05 2008-12-05 Piperazines as anti-obesity agents

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
SE0702696 2007-12-05
SE0702696-6 2007-12-05
US2298308P 2008-01-23 2008-01-23
PCT/EP2008/066877 WO2009071658A1 (en) 2007-12-05 2008-12-05 Piperazines as anti-obesity agents
US12/744,359 US20110059969A1 (en) 2007-12-05 2008-12-05 Piperazines as anti-obesity agents

Publications (1)

Publication Number Publication Date
US20110059969A1 true US20110059969A1 (en) 2011-03-10

Family

ID=40409928

Family Applications (3)

Application Number Title Priority Date Filing Date
US12/744,359 Abandoned US20110059969A1 (en) 2007-12-05 2008-12-05 Piperazines as anti-obesity agents
US12/315,698 Expired - Fee Related US7851471B2 (en) 2007-12-05 2008-12-05 Compounds I
US12/917,085 Abandoned US20110046135A1 (en) 2007-12-05 2010-11-01 New compounds i

Family Applications After (2)

Application Number Title Priority Date Filing Date
US12/315,698 Expired - Fee Related US7851471B2 (en) 2007-12-05 2008-12-05 Compounds I
US12/917,085 Abandoned US20110046135A1 (en) 2007-12-05 2010-11-01 New compounds i

Country Status (17)

Country Link
US (3) US20110059969A1 (enExample)
EP (1) EP2229362A1 (enExample)
JP (1) JP2011506294A (enExample)
KR (1) KR20100093104A (enExample)
CN (1) CN102026975A (enExample)
AU (1) AU2008333173A1 (enExample)
BR (1) BRPI0819989A2 (enExample)
CA (1) CA2707555A1 (enExample)
CO (1) CO6280487A2 (enExample)
CR (1) CR11479A (enExample)
DO (1) DOP2010000167A (enExample)
EA (1) EA201000926A1 (enExample)
EC (1) ECSP10010234A (enExample)
IL (1) IL205874A0 (enExample)
MX (1) MX2010006259A (enExample)
WO (1) WO2009071658A1 (enExample)
ZA (1) ZA201003976B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2715527A1 (en) * 2007-12-05 2009-06-11 Michael Higginbottom New compounds iv
CA2707248A1 (en) * 2007-12-05 2009-06-11 Astrazeneca Ab New compounds ii
KR101810975B1 (ko) * 2010-07-08 2017-12-20 에스케이바이오팜 주식회사 카바모일옥시 아릴알칸노일 아릴피페라진계 화합물을 포함하는 약학적 조성물
EP2683716A1 (en) 2011-03-11 2014-01-15 Glaxo Group Limited Pyrido[3,4-b]pyrazine derivatives as syk inhibitors
US11807622B2 (en) 2019-01-30 2023-11-07 Insilico Medicine Ip Limited TLR 9 inhibitors
US10689360B1 (en) * 2019-01-30 2020-06-23 Insilico Medicine Ip Limited TLR inhibitors
CN113149891B (zh) * 2020-01-07 2024-02-02 南京药石科技股份有限公司 一种2-氨基-2-（1-甲基-4-哌啶基）乙醇的制备方法
CN117777048B (zh) * 2023-09-25 2024-09-20 上海科利生物医药有限公司 一种手性2-羟甲基吗啉-4-羧酸叔丁酯的制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4670456A (en) * 1984-05-30 1987-06-02 Boehringer Ingelheim Kg 4-Aminocarbonylaminomethyl-1-benzylpyrrolidin-2-ones as nootropic agents and as agents for treating cerebral insufficiency

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20000016402A (ko) 1996-06-06 2000-03-25 피터 기딩스 렙틴(ob단백질)의 프레그먼트
US6057337A (en) * 1998-02-02 2000-05-02 Shiseido Co., Ltd. 1,2-DI-substituted piperidine derivative, hair growth promoter and external composition for skin using the same
JP2001131149A (ja) 1999-11-08 2001-05-15 Sumitomo Pharmaceut Co Ltd 選択的セロトニン再取り込み阻害剤
JP2001261657A (ja) 2000-03-17 2001-09-26 Yamanouchi Pharmaceut Co Ltd シアノフェニル誘導体
BR0114321A (pt) 2000-09-29 2003-07-01 Glaxo Group Ltd Composto, composição farmacêutica, uso de um composto, método de tratamento ou profilaxia de doenças inflamatórias, e, processo para preparar um composto
ES2197003B1 (es) * 2002-04-08 2005-03-16 J. URIACH & CIA S.A. Nuevos compuestos antagonistas de integrinas alfa.
EP1644347A1 (en) 2003-06-20 2006-04-12 Arena Pharmaceuticals, Inc. N-PHENYL-PIPERAZINE DERIVATIVES AND METHODS OF PROPHYLAXIS OR TREATMENT OF 5HT sb 2C /sb RECEPTOR ASSOCIATED DISEASES
CN102633730A (zh) * 2004-12-03 2012-08-15 先灵公司 作为cb1拮抗剂的取代哌嗪
DE102005000666B3 (de) 2005-01-04 2006-10-05 Sanofi-Aventis Deutschland Gmbh Sulfonylpyrrolidine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US20090325975A1 (en) 2005-07-15 2009-12-31 Helmut H Buschmann Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain
EP1787679A1 (en) 2005-07-29 2007-05-23 Laboratorios Del Dr. Esteve, S.A. Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain
US7790726B2 (en) 2005-08-16 2010-09-07 Chemocentryx, Inc. Monocyclic and bicyclic compounds and methods of use
EP1991211A1 (en) 2006-02-28 2008-11-19 Laboratorios Del Dr. Esteve, S.A. Use of compounds binding to the sigma receptor for the treatment of metabolic syndrome
CA2715527A1 (en) 2007-12-05 2009-06-11 Michael Higginbottom New compounds iv
CA2707822A1 (en) 2007-12-05 2009-06-11 Astrazeneca Ab New compounds iii
CA2707248A1 (en) 2007-12-05 2009-06-11 Astrazeneca Ab New compounds ii
US20110275670A1 (en) 2008-06-04 2011-11-10 Emma Chapman New Compounds VII
WO2009147211A1 (en) 2008-06-04 2009-12-10 Biovitrum Ab (Publ) New compounds v
CA2726270A1 (en) 2008-06-04 2009-12-10 Astrazeneca Ab Small molecule leptin receptor modulators
MX2010013359A (es) 2008-06-04 2011-04-07 Astrazeneca Ab Nuevos derivados de piridina como mimeticos moduladores del receptor de leptina.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4670456A (en) * 1984-05-30 1987-06-02 Boehringer Ingelheim Kg 4-Aminocarbonylaminomethyl-1-benzylpyrrolidin-2-ones as nootropic agents and as agents for treating cerebral insufficiency

Also Published As

Publication number Publication date
IL205874A0 (en) 2010-11-30
CR11479A (es) 2010-07-19
US20110046135A1 (en) 2011-02-24
CA2707555A1 (en) 2009-06-11
JP2011506294A (ja) 2011-03-03
US20090181967A1 (en) 2009-07-16
CO6280487A2 (es) 2011-05-20
ECSP10010234A (es) 2010-07-30
WO2009071658A1 (en) 2009-06-11
CN102026975A (zh) 2011-04-20
DOP2010000167A (es) 2010-06-30
BRPI0819989A2 (pt) 2015-05-12
MX2010006259A (es) 2010-08-23
US7851471B2 (en) 2010-12-14
ZA201003976B (en) 2011-04-28
KR20100093104A (ko) 2010-08-24
EA201000926A1 (ru) 2011-02-28
EP2229362A1 (en) 2010-09-22
AU2008333173A1 (en) 2009-06-11

Similar Documents

Publication Publication Date Title
US7851471B2 (en) Compounds I
US8093248B2 (en) Compounds useful for the treatment of conditions associated with weight gain
US20110275670A1 (en) New Compounds VII
US20090176798A1 (en) New compounds III
US20110275637A1 (en) Piperazine derivatives and their use as leptin receptor modulators
US20090203695A1 (en) Compounds IV
US20110275638A1 (en) Piperazine derivatives and their use as leptin receptor modulators
US20110275678A1 (en) New Pyridine Derivatives as Leptin Receptor Modulator Mimetics

Legal Events

Date Code Title Description
AS Assignment

Owner name: BIOVITRUM AB, SWEDEN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BOYD, JOSEPH W.;BROWN, GILES A.;HIGGINBOTTOM, MICHAEL;SIGNING DATES FROM 20100911 TO 20100917;REEL/FRAME:025610/0380

Owner name: ASTRAZENECA AB, SWEDEN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BIOVITRUM AB;REEL/FRAME:025610/0598

Effective date: 20100918

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION